U.S. markets close in 2 hours 10 minutes
  • S&P 500

    3,771.07
    +92.64 (+2.52%)
     
  • Dow 30

    30,159.14
    +668.25 (+2.27%)
     
  • Nasdaq

    11,117.26
    +301.83 (+2.79%)
     
  • Russell 2000

    1,759.88
    +51.01 (+2.98%)
     
  • Crude Oil

    86.54
    +2.91 (+3.48%)
     
  • Gold

    1,731.30
    +29.30 (+1.72%)
     
  • Silver

    21.09
    +0.51 (+2.46%)
     
  • EUR/USD

    0.9973
    +0.0146 (+1.49%)
     
  • 10-Yr Bond

    3.6190
    -0.0320 (-0.88%)
     
  • GBP/USD

    1.1455
    +0.0135 (+1.20%)
     
  • USD/JPY

    144.1040
    -0.5160 (-0.36%)
     
  • BTC-USD

    19,958.17
    +396.42 (+2.03%)
     
  • CMC Crypto 200

    453.55
    +8.12 (+1.82%)
     
  • FTSE 100

    7,086.46
    +177.70 (+2.57%)
     
  • Nikkei 225

    26,992.21
    +776.42 (+2.96%)
     

Minerva Surgical to Present at the H.C. Wainwright 24th Annual Global Investment Conference

·1 min read
Minerva Surgical, Inc.
Minerva Surgical, Inc.

SANTA CLARA, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that its management will present at the H.C. Wainwright 24th Annual Global Investment Conference. The presentation will be available on-demand for registered participants through the H.C. Wainwright conference portal starting at 7:00 a.m. Eastern Time on Monday, September 12, 2022.

About Minerva Surgical, Inc.

Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. The Company has established a broad product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of Abnormal Uterine Bleeding (AUB) in most uterine anatomies. The Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies.

MEDIA CONTACT

Mike Clapper
mike.clapper@minervasurgical.com
804-295-7676

INVESTOR RELATIONS CONTACT

Caroline Corner
investors@minervasurgical.com
415-202-5678

RELATED LINKS

https://www.aubandme.com

https://www.minervasurgical.com